Celldex Therapeutics, Inc. (CLDX) earnings per share (EPS)
Celldex Therapeutics, Inc. (CLDX) reported diluted earnings per share of -$3.90 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$2.45. Figures as of 17 Nov 2026, 18:13 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings per share, fiscal 2025
- -$3.90
- Highest on record
- -$1.64fiscal 2021
- Lowest on record
- -$3.90fiscal 2025
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Celldex Therapeutics, Inc. earnings per share (EPS), in more detail
Across the 7 fiscal years on record (2019–2025), the highest was -$1.64 in fiscal 2021 and the lowest -$3.90 in fiscal 2025.
Earnings per share by fiscal year
Celldex Therapeutics, Inc. earnings per share (EPS), year by year
| Fiscal year | Earnings per share | Change | Year ended |
|---|---|---|---|
| 2025 | -$3.90 | — | |
| 2024 | -$2.45 | — | |
| 2023 | -$2.92 | — | |
| 2022 | -$2.40 | — | |
| 2021 | -$1.64 | — | |
| 2020 | -$2.02 | — | |
| 2019 | -$3.51 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.
How to read it
It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.
Celldex Therapeutics, Inc., figure by figure
- Celldex Therapeutics, Inc. market cap
- Celldex Therapeutics, Inc. revenue
- Celldex Therapeutics, Inc. earnings
- Celldex Therapeutics, Inc. P/E ratio
- Celldex Therapeutics, Inc. P/S ratio
- Celldex Therapeutics, Inc. P/B ratio
- Celldex Therapeutics, Inc. free cash flow
- Celldex Therapeutics, Inc. operating margin
- Celldex Therapeutics, Inc. dividend
- Celldex Therapeutics, Inc. shares outstanding
- Celldex Therapeutics, Inc. total debt
- Celldex Therapeutics, Inc. cash on hand
- Celldex Therapeutics, Inc. total assets
- Celldex Therapeutics, Inc. return on equity (ROE)
- Celldex Therapeutics, Inc. return on invested capital (ROIC)
Celldex Therapeutics, Inc. (CLDX) overview: price, valuation and scorecard
Celldex Therapeutics, Inc. earnings per share (EPS): questions and answers
What is Celldex Therapeutics, Inc.'s diluted earnings per share?
Celldex Therapeutics, Inc. (CLDX) reported diluted earnings per share of -$3.90 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$2.45.
What are the highest and lowest diluted earnings per share figures on record for Celldex Therapeutics, Inc.?
Across the 7 fiscal years on record (2019–2025), the highest was -$1.64 in fiscal 2021 and the lowest -$3.90 in fiscal 2025.
How is Celldex Therapeutics, Inc.'s diluted earnings per share calculated?
Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.
Fiscal years are named for the calendar year they end in.
Learn: earnings per share (EPS)
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Celldex Therapeutics, Inc. (CLDX) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/CLDX/eps
Underlying data: the company's filings with the SEC and Yahoo Finance.